Medicine and Dentistry
Acute Exacerbation of Chronic Obstructive Pulmonary Disease
35%
Angiogenesis
32%
Artificial Respiration
16%
Auriculotherapy
16%
Bevacizumab
8%
Bladder Cancer
16%
Body Mass Index
6%
Braden Scale
7%
Breast Cancer
16%
Case-Control Study
16%
Chest Wall Oscillation
16%
Cholesterol Synthesis
16%
Chronic Obstructive Pulmonary Disease
65%
Cohort Analysis
16%
Combination Therapy
16%
Endurance Training
16%
Epidermal Growth Factor Receptor
16%
Exercise
32%
Farnesoid X Receptor
16%
Gastroesophageal Reflux
49%
Gefitinib
10%
Hydroxymethylglutaryl Coenzyme A Reductase Kinase
16%
Injury
16%
Intensive Care Unit
16%
Leukocyte
7%
Leukopenia
16%
Liver Cirrhosis
16%
Lung Adenocarcinoma
12%
Maturity Onset Diabetes of the Young
5%
Meta-Analysis
49%
Noninvasive Positive Pressure Ventilation
16%
Noninvasive Ventilation
10%
Quality of Life
32%
Randomized Controlled Trial
34%
Sequential Analysis
16%
Sputum
9%
Symptom
29%
Systematic Review
32%
Thiazolidinedione
16%
Transitional Cell Carcinoma
7%
Nursing and Health Professions
Adverse Event
16%
Albumin Level
5%
Artificial Respiration
16%
Aspiration Pneumonia
5%
Auriculotherapy
16%
Baccalaureate Nursing Student
16%
Body Composition
16%
Body Mass
6%
Braden Scale
7%
Breast Cancer
16%
Case-Control Study
16%
Checklist
5%
Chest Wall Oscillation
16%
CINAHL
5%
Cohort Analysis
16%
Continuous Positive Airway Pressure
16%
Cross-Sectional Study
16%
Digestive System Ulcer
5%
Embase
5%
Emergency Care
16%
Fat Mass
6%
Gastroesophageal Reflux
32%
Hospitalization
8%
Hydrocortisone
16%
Intensive Care
16%
Intensive Care Unit
28%
Leukopenia
16%
Liver Cirrhosis
16%
Longitudinal Analysis
16%
Medline
5%
Meta Analysis
49%
Noninvasive Ventilation
10%
Obstructive Lung Disease
49%
Patient Care
16%
Pressure Injury
16%
Quality of Life
32%
Self Care
16%
Sequential Analysis
16%
Symptom
16%
Systematic Review
32%
Walking Distance
6%
Pharmacology, Toxicology and Pharmaceutical Science
Adrenergic Receptor Stimulating Agent
16%
Atorvastatin
5%
Auriculotherapy
16%
Bevacizumab
7%
Bile Acid
6%
Bladder Cancer
16%
Breast Cancer
16%
Bronchodilating Agent
16%
Chemotherapy
16%
Chronic Obstructive Lung Disease
100%
Cohort Study
32%
Combination Therapy
16%
Epidermal Growth Factor Receptor
16%
Farnesoid X Receptor
32%
Gastroesophageal Reflux
65%
Gefitinib
9%
Hydroxymethylglutaryl Coenzyme A Reductase Kinase
16%
Ischemia
16%
Leukopenia
16%
Lung Adenocarcinoma
13%
Lung Cancer
18%
Non Insulin Dependent Diabetes Mellitus
5%
Randomized Controlled Trial
18%
Statin (Protein)
18%
Sterol Regulatory Element Binding Protein 2
6%
Symptom
31%
Thiazolidinedione
16%
Transitional Cell Carcinoma
7%